These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

704 related articles for article (PubMed ID: 23021247)

  • 21. A demand for next-generation oncolytic adenoviruses.
    Hermiston T
    Curr Opin Mol Ther; 2006 Aug; 8(4):322-30. PubMed ID: 16955695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles.
    Loskog A
    Viruses; 2015 Nov; 7(11):5780-91. PubMed ID: 26561829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in oncolytic adenovirus therapies for cancer.
    Rosewell Shaw A; Suzuki M
    Curr Opin Virol; 2016 Dec; 21():9-15. PubMed ID: 27379906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncolytic Immunotherapy.
    Hennessy ML; Bommareddy PK; Boland G; Kaufman HL
    Surg Oncol Clin N Am; 2019 Jul; 28(3):419-430. PubMed ID: 31079797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Genetic, immunological, and pharmacological strategies to generate improved oncolytic viruses].
    Pol J; Le Bœuf F; Diallo JS
    Med Sci (Paris); 2013 Feb; 29(2):165-73. PubMed ID: 23452603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncolytic Viruses: Therapeutics With an Identity Crisis.
    Breitbach CJ; Lichty BD; Bell JC
    EBioMedicine; 2016 Jul; 9():31-36. PubMed ID: 27407036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Next-generation oncolytic vaccinia vectors.
    Thorne SH
    Methods Mol Biol; 2012; 797():205-15. PubMed ID: 21948478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrating oncolytic viruses in combination cancer immunotherapy.
    Bommareddy PK; Shettigar M; Kaufman HL
    Nat Rev Immunol; 2018 Aug; 18(8):498-513. PubMed ID: 29743717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The chicken chorioallantoic membrane tumor assay as model for qualitative testing of oncolytic adenoviruses.
    Durupt F; Koppers-Lalic D; Balme B; Budel L; Terrier O; Lina B; Thomas L; Hoeben RC; Rosa-Calatrava M
    Cancer Gene Ther; 2012 Jan; 19(1):58-68. PubMed ID: 22015640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modification of oncolytic adenovirus and its application in cancer therapy.
    Liang Y; He J; Zhao Y
    Discov Med; 2020; 30(161):129-144. PubMed ID: 33593481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of oncolytic adenoviruses with chemotherapies: an overview and future directions.
    Bressy C; Benihoud K
    Biochem Pharmacol; 2014 Jul; 90(2):97-106. PubMed ID: 24832861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Introduction to Oncolytic Virotherapy.
    Engeland CE; Bell JC
    Methods Mol Biol; 2020; 2058():1-6. PubMed ID: 31486028
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oncolytic adenovirus: A tool for reversing the tumor microenvironment and promoting cancer treatment (Review).
    Wang X; Zhong L; Zhao Y
    Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33760203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combining IL-10 and Oncolytic Adenovirus Demonstrates Enhanced Antitumor Efficacy Through CD8
    Chen D; Huang L; Zhou H; Zhang Y
    Front Immunol; 2021; 12():615089. PubMed ID: 33717103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolution of oncolytic viruses: novel strategies for cancer treatment.
    Atherton MJ; Lichty BD
    Immunotherapy; 2013 Nov; 5(11):1191-206. PubMed ID: 24188674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor Targeting of Oncolytic Adenoviruses Using Bispecific Adapter Proteins.
    Niemann J; Kühnel F
    Methods Mol Biol; 2020; 2058():31-49. PubMed ID: 31486030
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunological effects of a tumor necrosis factor alpha-armed oncolytic adenovirus.
    Hirvinen M; Rajecki M; Kapanen M; Parviainen S; Rouvinen-Lagerström N; Diaconu I; Nokisalmi P; Tenhunen M; Hemminki A; Cerullo V
    Hum Gene Ther; 2015 Mar; 26(3):134-44. PubMed ID: 25557131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deletion of the E3-6.7K/gp19K region reduces the persistence of wild-type adenovirus in a permissive tumor model in Syrian hamsters.
    Bortolanza S; Bunuales M; Alzuguren P; Lamas O; Aldabe R; Prieto J; Hernandez-Alcoceba R
    Cancer Gene Ther; 2009 Sep; 16(9):703-12. PubMed ID: 19229289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
    Hamdan F; Ylösmäki E; Chiaro J; Giannoula Y; Long M; Fusciello M; Feola S; Martins B; Feodoroff M; Antignani G; Russo S; Kari O; Lee M; Järvinen P; Nisen H; Kreutzman A; Leusen J; Mustjoki S; McWilliams TG; Grönholm M; Cerullo V
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Newcastle disease virus: a promising agent for tumour immunotherapy.
    Zhao L; Liu H
    Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):725-30. PubMed ID: 22211810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.